SEBI Registration No - INA000003197 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS.

Blog

granuals

Granules India receives EIR at Jeedimetla facility

This facility had received one form 483 observation during the last inspection.

Granules India has announced that USFDA has issued Establishment Inspection Report (EIR) for its Jeedimetla facility located at Hyderabad, Telangana, India.

This facility had received one form 483 observation during the last USFDA inspection in March 2018. The company’s response to the USFDA was within the stipulated timeframe and USFDA has found it satisfactory and hence It has received the EIR on this facility.

Jeedimetla facility manufactures Active Pharmaceutical Ingredients and Pharmaceutical Formulation Intermediates.

Granules India Ltd is currently trading at Rs94.60 down by Rs0.05 or 0.05% from its previous closing of Rs94.65 on the BSE. The scrip opened at Rs94 and has touched a high and low of Rs95.75 and Rs92.90 respectively. So far 12,18,763 (NSE+BSE) shares were traded on the counter.